Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Zhonghua Xue Ye Xue Za Zhi ; 38(9): 778-783, 2017 Sep 14.
Article in Chinese | MEDLINE | ID: mdl-29081195

ABSTRACT

Objective: To investigate the impact of intensified maintenance therapy on the prognosis of children and adolescents with advanced lymphoblastic lymphoma (LBL) . Methods: Retrospective analysis on the treatment results of children and adolescents with stage Ⅲ and stage Ⅳ LBL who underwent BFM-NHL-90/-95 regimen without prophylactic radiotherapy. The intensified therapy group included the patients admitted from 1998 to 2005, while others were classified as the non-intensified therapy group. Patients in the intensified therapy group were intravenously treated with "etoposide phosphate plus cytrarabine" and high-dose methotrexate alternately per 2.5-3 months in addition to the oral chemotherapy with 6-mercaptopurine and methotrexate during the maintenance phase. Results: A total of 187 LBL patients were enrolled. The rates of 5-year event free survival were (76.9 ± 5.8) % and (77.9 ± 4.3) % (χ(2)=0.249, P=0.617) respectively, in the intensified therapy (n=52) and the non-intensified therapy groups (n=135) , while the rates of 5-year overall survival of them were (78.8 ± 5.7) % and (79.8±4.1) % (χ(2)=0.353, P=0.552) , respectively. Stratified by stage, immunological type as well as risk stratification, the rates of long-term survival were similar between the two groups. During the maintenance phase, the rates of grade Ⅲ and Ⅳ myelosuppression in the intensified therapy and the non-intensified maintenance groups were 55.8% and 18.5%, respectively (χ(2)=25.363, P<0.05) . Conclusion: Intensified maintenance therapy failed to improve the prognosis of patients with advanced LBL.


Subject(s)
Precursor Cell Lymphoblastic Leukemia-Lymphoma , Antineoplastic Combined Chemotherapy Protocols , Child , Disease-Free Survival , Humans , Methotrexate , Prognosis , Retrospective Studies , Treatment Outcome
2.
Psychol Med ; 46(15): 3219-3230, 2016 11.
Article in English | MEDLINE | ID: mdl-27604840

ABSTRACT

BACKGROUND: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus with impaired glucose tolerance (IGT) than normals. We examined the relationship between IGT and clinical phenotypes or cognitive deficits in first-episode, drug-naïve (FEDN) Han Chinese patients with schizophrenia. METHOD: A total of 175 in-patients were compared with 31 healthy controls on anthropometric measures and fasting plasma levels of glucose, insulin and lipids. They were also compared using a 75 g oral glucose tolerance test and the homeostasis model assessment of insulin resistance (HOMA-IR). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). RESULTS: Of the patients, 24.5% had IGT compared with none of the controls, and they also had significantly higher levels of fasting blood glucose and 2-h glucose after an oral glucose load, and were more insulin resistant. Compared with those patients with normal glucose tolerance, the IGT patients were older, had a later age of onset, higher waist or hip circumference and body mass index, higher levels of low-density lipoprotein and triglycerides and higher insulin resistance. Furthermore, IGT patients had higher PANSS total and negative symptom subscale scores, but no greater cognitive impairment except on the emotional intelligence index of the MCCB. CONCLUSIONS: IGT occurs with greater frequency in FEDN schizophrenia, and shows association with demographic and anthropometric parameters, as well as with clinical symptoms but minimally with cognitive impairment during the early course of the disorder.


Subject(s)
Cognitive Dysfunction/physiopathology , Glucose Intolerance/metabolism , Schizophrenia/physiopathology , Schizophrenic Psychology , Adult , Age of Onset , Blood Glucose/metabolism , Body Mass Index , Case-Control Studies , Cognitive Dysfunction/complications , Cognitive Dysfunction/psychology , Fasting , Female , Glucose Intolerance/complications , Glucose Tolerance Test , Hospitalization , Humans , Insulin/metabolism , Insulin Resistance , Lipoproteins, LDL/metabolism , Male , Phenotype , Schizophrenia/complications , Triglycerides/metabolism , Waist Circumference , Young Adult
3.
Chemotherapy ; 55(5): 372-80, 2009.
Article in English | MEDLINE | ID: mdl-19707016

ABSTRACT

BACKGROUND: Potassium channel blockers have been shown to possess antitumor properties, but the role of apoptosis remains to be clarified. In this study, we investigated the antiproliferative effect of tetraethylammonium (TEA), a nonspecific potassium channel blocker, in rat C6 and 9L glioma cells. METHODS: Cytotoxicity was evaluated by MTT assay. Apoptosis was detected by TUNEL and annexin V-FITC/propidium iodide assays. Protein levels were determined by Western blot analysis. Intracellular reactive oxygen species (ROS) levels were assessed flow cytometrically. RESULTS: TEA (2-60 mM) significantly inhibited the proliferation of C6 and 9L glioma cells. In addition, increased cell apoptosis was confirmed after treatment with 40 mM TEA. Apoptosis was associated with a dramatic increase in ROS levels and altered Bcl-2/Bax protein balance. CONCLUSION: TEA can inhibit proliferation and induce apoptosis in both cell lines; therefore, it might be associated with the increase in intracellular ROS production.


Subject(s)
Antineoplastic Agents/therapeutic use , Glioma/drug therapy , Potassium Channel Blockers/therapeutic use , Reactive Oxygen Species/metabolism , Tetraethylammonium/therapeutic use , Animals , Apoptosis , Cell Line, Tumor , Cell Survival/drug effects , Glioma/metabolism , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...